title: Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma.
abstract: OBJECTIVE
  To evaluate use of a radiolabeled peptide nucleic acid-peptide conjugate (RaPP) targeting B-cell leukemia-lymphoma 2 (BCL2) mRNA for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma and to assess associations among RaPP uptake, time to tumor progression (TTP), and BCL2 mRNA expression.
  
  
  METHODS
  11 dogs with B-cell lymphoma and 1 clinically normal dog.
  
  
  METHODS
  Scintigraphic images were acquired 1 hour after IV injection of the RaPP. Regions of interest (ROIs) were drawn around lymph nodes, liver, and spleen; ROI intensity (relative to that of an equally sized region of muscle in the same image) was measured. Each ROI was also subjectively categorized as positive or negative for increased RaPP uptake. Expression of BCL2 mRNA was determined via quantitative reverse transcriptase PCR assay of a lymph node sample from dogs with lymphoma. Associations among imaging results, TTP, and BCL2 mRNA expression were evaluated.
  
  
  RESULTS
  Increased RaPP uptake was detected in affected tissues of dogs with lymphoma. Dogs with superficial cervical lymph node ROIs categorized as negative (n = 8) for increased RaPP uptake had a significantly longer TTP than did dogs for which this ROI was considered positive (2). Measured intensity of mandibular and superficial cervical lymph node ROIs was negatively associated with TTP. Associations among BCL2 mRNA and ROI intensity or TTP were not significant.
  
  
  CONCLUSIONS
  Increased RaPP uptake at mandibular or superficial cervical lymph node ROIs may be a negative prognostic indicator in dogs with lymphoma. A larger investigation is needed to determine clinical value of the RaPP for disease detection and prognostication.
authors.affiliation: Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Statham-Ringen
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Selting
authors.forename: Jimmy C
authors.initials: JC
authors.lastname: Lattimer
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Henry
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Green
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Bryan
authors.forename: Fang
authors.initials: F
authors.lastname: Jia
authors.forename: Michael R
authors.initials: MR
authors.lastname: Lewis
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000000981:diagnostic imaging* / Q000473:pathology; D004285:Dogs; D005260:Female; D007205:Indium Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics; D007275:Injections, Intravenous / Q000662:veterinary; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D008214:Lymphocytes / Q000000981:diagnostic imaging* / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000378:metabolism / Q000662:veterinary*; D008297:Male; D020135:Peptide Nucleic Acids / Q000737:chemistry / Q000493:pharmacokinetics; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011877:Radionuclide Imaging / Q000379:methods* / Q000662:veterinary; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D007205:Indium Radioisotopes; D020135:Peptide Nucleic Acids; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D019275:Radiopharmaceuticals